NCT04640012View on ClinicalTrials.gov

Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

March 19, 2021

Study Completion Date

March 15, 2022

Conditions
Hyperlipidemia
Interventions
DRUG

DC371739

Participants received one of 6 dose levels of DC371739 administered as single oral doses.

DRUG

Placebo

Placebo orally administered

Trial Locations (1)

200031

Shanghai Xu hui Central Hospital, Shanghai

All Listed Sponsors
lead

Guangzhou JOYO Pharma Co., Ltd

INDUSTRY

NCT04640012 - Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects | Biotech Hunter | Biotech Hunter